EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 103 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,259 | -63.2% | 112,323 | -15.1% | 0.00% | – |
| Q2 2023 | $93,158 | -74.1% | 132,328 | -67.0% | 0.00% | – |
| Q1 2023 | $359,995 | -25.4% | 401,377 | -1.8% | 0.00% | – |
| Q4 2022 | $482,317 | -84.1% | 408,743 | +1.6% | 0.00% | -100.0% |
| Q3 2022 | $3,028,000 | +22.2% | 402,159 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $2,477,000 | -7.7% | 393,080 | +21.6% | 0.00% | – |
| Q1 2022 | $2,683,000 | +54.2% | 323,273 | -3.6% | 0.00% | – |
| Q4 2021 | $1,740,000 | -23.9% | 335,210 | -2.0% | 0.00% | – |
| Q3 2021 | $2,285,000 | -24.5% | 342,051 | -3.7% | 0.00% | -100.0% |
| Q2 2021 | $3,025,000 | -8.5% | 355,153 | -4.9% | 0.00% | 0.0% |
| Q1 2021 | $3,306,000 | -37.6% | 373,562 | -13.4% | 0.00% | 0.0% |
| Q4 2020 | $5,302,000 | +57.5% | 431,433 | +4.3% | 0.00% | 0.0% |
| Q3 2020 | $3,367,000 | -9.5% | 413,777 | +6.7% | 0.00% | 0.0% |
| Q2 2020 | $3,722,000 | +70.0% | 387,633 | +20.4% | 0.00% | 0.0% |
| Q1 2020 | $2,189,000 | -51.6% | 321,940 | +6.1% | 0.00% | 0.0% |
| Q4 2019 | $4,521,000 | +47.8% | 303,435 | +1.7% | 0.00% | 0.0% |
| Q3 2019 | $3,059,000 | +224.7% | 298,442 | +235.9% | 0.00% | – |
| Q2 2019 | $942,000 | +19.5% | 88,861 | +57.7% | 0.00% | – |
| Q1 2019 | $788,000 | +27.7% | 56,359 | -7.2% | 0.00% | – |
| Q4 2018 | $617,000 | +8.6% | 60,750 | +28.3% | 0.00% | – |
| Q3 2018 | $568,000 | +14.7% | 47,345 | +16.8% | 0.00% | – |
| Q2 2018 | $495,000 | +71.3% | 40,552 | +38.0% | 0.00% | – |
| Q1 2018 | $289,000 | +90.1% | 29,376 | +169.7% | 0.00% | – |
| Q4 2017 | $152,000 | -67.8% | 10,893 | -73.6% | 0.00% | – |
| Q1 2017 | $472,000 | +6.5% | 41,227 | +8.5% | 0.00% | – |
| Q4 2016 | $443,000 | -11.0% | 38,011 | +2.1% | 0.00% | – |
| Q3 2016 | $498,000 | -25.4% | 37,212 | +10.4% | 0.00% | – |
| Q2 2016 | $668,000 | – | 33,717 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |